APA (7th ed.) Citation

Risi, B., Ait Allali, N., Cotti Piccinelli, S., Caria, F., Damioli, S., Labella, B., . . . Filosto, M. (2025). Assessing the Safety and Efficacy of Lamotrigine as Anti-myotonic Agent in Myotonic Dystrophy Type 1 (DM1): A Longitudinal, Open-Label, Pilot Study. Neurology & Therapy, 14(5), 2249. https://doi.org/10.1007/s40120-025-00804-z

Chicago Style (17th ed.) Citation

Risi, Barbara, et al. "Assessing the Safety and Efficacy of Lamotrigine as Anti-myotonic Agent in Myotonic Dystrophy Type 1 (DM1): A Longitudinal, Open-Label, Pilot Study." Neurology & Therapy 14, no. 5 (2025): 2249. https://doi.org/10.1007/s40120-025-00804-z.

MLA (9th ed.) Citation

Risi, Barbara, et al. "Assessing the Safety and Efficacy of Lamotrigine as Anti-myotonic Agent in Myotonic Dystrophy Type 1 (DM1): A Longitudinal, Open-Label, Pilot Study." Neurology & Therapy, vol. 14, no. 5, 2025, p. 2249, https://doi.org/10.1007/s40120-025-00804-z.